Can the anesthetic management affect oncological outcome in lung cancer surgery?

Purpose of the review Lung cancer surgery creates a vulnerable perioperative window where anesthetic and physiological interventions may modulate recurrence. This review evaluates the oncological impact of perioperative strategies in non-small-cell lung cancer, proposing a comprehensive ‘oncoanesthesia care bundle’. Recent findings Current clinical data expose a persistent gap between compelling preclinical rationales and observable clinical outcomes. The recent General Anesthetics in CAncer REsection Surgery (2026), a large-scale evaluation of propofol versus volatile anesthesia, enrolled mixed cancer cohorts and demonstrated no oncological advantage of propofol, underscoring that the ongoing Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia trial will provide the first adequately powered, lung cancer-specific evaluation. Similarly, prospective randomized data regarding regional anesthesia have failed to show a significant recurrence benefit in lung cancer surgery. For nonsteroidal anti-inflammatory drugs, the Adjuvant Low-dose ASpirin in Colorectal CAncer trial’s recent biomarker-driven success in colorectal cancer highlights the urgent necessity for analogous molecularly tailored investigations in non-small-cell lung cancer. Beyond pharmacological agents, meticulous physiological optimization remains critical: lung-protective ventilation, restrictive-to-euvolemic fluid management, and maintaining normothermia are biologically coherent strategies that preserve the endothelial glycocalyx, optimize interstitial fluid pressure, and maintain natural killer cell function. Summary Current clinical evidence does not justify selecting individual anesthetic agents solely for oncological benefit. Nevertheless, combining tailored pharmacological strategies, specifically opioid-sparing multimodal analgesia, with meticulous physiological optimization into a structured ‘oncoanesthesia care bundle’ provides a biologically coherent, low-risk framework available for immediate implementation. Future oncological trials must shift from pragmatic pan-cancer designs toward large-scale, patient-, cancer-, and gene-expression-specific trial protocols to truly capture personalized oncological outcomes.

Authors

Institutions

Publication Details

Journal
Current Opinion in Anaesthesiology
Published
2026-11-14
DOI
https://doi.org/10.1097/aco.0000000000001722
Primary Topic
Cancer, Stress, Anesthesia, and Immune Response
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Can the anesthetic management affect oncological outcome in lung cancer surgery?

Hyun Joo Ahn, Jeayoun Kim, Ji Won Choi
Current Opinion in Anaesthesiology
Cancer, Stress, Anesthesia, and Immune Response
article

Can the anesthetic management affect oncological outcome in lung cancer surgery?

Hyun Joo Ahn, Jeayoun Kim, Ji Won Choi
article en

Abstract

Purpose of the review Lung cancer surgery creates a vulnerable perioperative window where anesthetic and physiological interventions may modulate recurrence. This review evaluates the oncological impact of perioperative strategies in non-small-cell lung cancer, proposing a comprehensive ‘oncoanesthesia care bundle’. Recent findings Current clinical data expose a persistent gap between compelling preclinical rationales and observable clinical outcomes. The recent General Anesthetics in CAncer REsection Surgery (2026), a large-scale evaluation of propofol versus volatile anesthesia, enrolled mixed cancer cohorts and demonstrated no oncological advantage of propofol, underscoring that the ongoing Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia trial will provide the first adequately powered, lung cancer-specific evaluation. Similarly, prospective randomized data regarding regional anesthesia have failed to show a significant recurrence benefit in lung cancer surgery. For nonsteroidal anti-inflammatory drugs, the Adjuvant Low-dose ASpirin in Colorectal CAncer trial’s recent biomarker-driven success in colorectal cancer highlights the urgent necessity for analogous molecularly tailored investigations in non-small-cell lung cancer. Beyond pharmacological agents, meticulous physiological optimization remains critical: lung-protective ventilation, restrictive-to-euvolemic fluid management, and maintaining normothermia are biologically coherent strategies that preserve the endothelial glycocalyx, optimize interstitial fluid pressure, and maintain natural killer cell function. Summary Current clinical evidence does not justify selecting individual anesthetic agents solely for oncological benefit. Nevertheless, combining tailored pharmacological strategies, specifically opioid-sparing multimodal analgesia, with meticulous physiological optimization into a structured ‘oncoanesthesia care bundle’ provides a biologically coherent, low-risk framework available for immediate implementation. Future oncological trials must shift from pragmatic pan-cancer designs toward large-scale, patient-, cancer-, and gene-expression-specific trial protocols to truly capture personalized oncological outcomes.

Current Opinion in Anaesthesiology
Samsung Medical Center (KR), Sungkyunkwan University (KR)
Cancer, Stress, Anesthesia, and Immune Response
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon